Clinical Significance of Different Profiles of anti-Ro Antibodies in Connective Tissue Diseases

被引:6
|
作者
Yang, Hai-Tao [1 ,2 ]
Hong, Xiao-Ping [1 ,2 ]
Guo, Jie-Wen [3 ]
Zhong, Xiao-Ling [2 ,4 ]
Liao, Rui [3 ]
Liu, Cui-Lian [1 ,2 ]
Liu, Li-Xiong [1 ,2 ]
Li, Kai [1 ,2 ]
Chen, Yu-Lan [1 ,2 ]
Liu, Dong-Zhou [1 ,2 ]
机构
[1] Jinan Univ, Shenzhen Peoples Hosp, Dept Rheumatol & Immunol, Clin Med Coll 2, Shenzhen, Guangdong, Peoples R China
[2] Southern Univ Sci & Technol, Affiliated Hosp 1, Shenzhen, Guangdong, Peoples R China
[3] Jinan Univ, Shenzhen Peoples Hosp, Clin Med Coll 2, Shenzhen, Guangdong, Peoples R China
[4] Jinan Univ, Shenzhen Peoples Hosp, Dept Radiol, Clin Med Coll 2, Shenzhen, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
SOCIETY CLASSIFICATION CRITERIA; PRIMARY SJOGRENS-SYNDROME; AMERICAN-COLLEGE; RHEUMATOLOGY/EUROPEAN LEAGUE; ANTI-RO52; ANTIBODIES; SYSTEMIC-SCLEROSIS; REVISED CRITERIA; DATA-DRIVEN; CONSENSUS; SPONDYLOARTHRITIS;
D O I
10.1155/2023/9195157
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective. Anti-Ro60 and anti-Ro52 antibodies are associated with different connective tissue diseases (CTDs). However, the clinical significance of anti-Ro antibodies is not always consistent among different global regions. The aim of this study was to investigate the clinical characteristics of patients with anti-Ro antibodies. Methods. A total of 1596 inpatients with anti-Ro antibodies were included in the study. Demographic, clinical, and serological data were compared between individuals with different profiles of anti-Ro antibodies: patients with anti-Ro52 antibodies alone, patients with anti-Ro60 antibodies alone, and patients with combined anti-Ro52 and anti-Ro60 antibodies. Results. Of the 1596 patients, 1362 (85.3%) were female, the mean age was 45.5 years, and systemic lupus erythematosus (SLE) (46.0%) and Sjogren's syndrome (SS) (19.0%) were the most common CTD diagnoses. Among the patients with anti-Ro52 antibodies alone, idiopathic inflammatory myopathy (18.8%) and SLE (17.6%) were the most common CTD diagnoses. The coexistent autoantibodies of this group were significantly lower compared with those of the other two groups, while the presence of anti-Jo1 antibodies were significantly higher compared with those of the other two groups (3.7% vs. 0.6% vs. 1.9%, p=0.029). In addition, the patients with isolated anti-Ro52 antibodies were more likely to suffer from interstitial lung disease (35.5% vs. 11.3% vs. 13.7%, p < 10-4) and pulmonary arterial hypertension (10.1% vs. 5.3% vs. 3.6%, p=0.001) compared with the other two groups of patients. Compared with patients with isolated anti-Ro52 or anti-Ro60 antibodies, the patients with combined anti-Ro52 and anti-Ro60 antibodies were more likely to suffer from xerophthalmia and xerostomia. Furthermore, hypocomplementemia, hyperglobulinemia, and proteinuria were particularly prevalent in patients with anti-Ro60 antibodies. Conclusion. Different profiles of anti-Ro antibodies were significantly associated with clinical phenotypic features in CTDs, indicating the potential diagnostic and prognostic value of these antibodies in clinical practice.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Frequency and significance of anti-Ro (SS-A) antibodies in multiple sclerosis patients
    de Andrés, C
    Guillem, A
    Rodríguez-Mahou, M
    Longo, FJL
    ACTA NEUROLOGICA SCANDINAVICA, 2001, 104 (02): : 83 - 87
  • [22] Clinical significance of antibodies to denatured 52 KD Ro/SS-A protein in patients with unselected connective tissue diseases.
    Carreno, L
    Grau, R
    Monteagudo, I
    Moreno, AC
    Gonzalez, C
    Godoy, H
    FernandezEspartero, MC
    LopezLongo, FJ
    ARTHRITIS AND RHEUMATISM, 1997, 40 (09): : 1042 - 1042
  • [23] Clinical significance of anti-Ro/SSA-52 kDa antibodies-a retrospective monocentric study
    Hervier, Baptiste
    Rimbert, Marie
    Colonna, Francoise
    Hamidou, Mohammed A.
    Audrain, Marie
    RHEUMATOLOGY, 2009, 48 (08) : 964 - 967
  • [24] Clinical Significance of Anti-Ro/SSA Antibodies in Patients with Systemic Sclerosis: A Study from the EUSTAR Database
    Burja, Blaz
    Boubaya, Marouane
    Carreira, Patricia
    Bergmann, Christina
    Ananieva, Lidia P.
    Riemekasten, Gabriela
    Masado, Okada
    de Vries-Bouwstra, Jeska
    Rosato, Edoardo
    Truchetet, Marie-Elise
    Del Papa, Nicoletta
    Marcoccia, Antonella
    Atzeni, Fabiola
    Schmeiser, Tim
    Vonk, Madelon
    Del Galdo, Francesco
    Distler, Oliver
    Elhai, Muriel
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 1248 - 1251
  • [25] An updated review of anti-Ro52 (TRIM21) antibodies impact in connective tissue diseases clinical management
    Decker, P.
    Moulinet, T.
    Pontille, F.
    Cravat, M.
    Bittencourt, M. De Carvalho
    Jaussaud, R.
    AUTOIMMUNITY REVIEWS, 2022, 21 (03)
  • [26] Anti-Ro/SSA antibodies in rheumatoid arthritis: Clinical and immunologic associations
    Cavazzana, I
    Franceschini, F
    Quinzanini, M
    Manera, C
    Del Papa, N
    Maglione, W
    Comina, D
    Radice, A
    Sinico, RA
    Cattaneo, R
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2006, 24 (01) : 59 - 64
  • [27] Clinical Significance of Anti-Ro52 Antibody in Chinese Patients with Connective Tissue Diseases: A Single-Center Experience
    Wu, Si
    Tang, Xiaojun
    Feng, Xuebing
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [28] Anti-Ro/SSA and La/SSB antibodies
    Franceschini, F
    Cavazzana, I
    AUTOIMMUNITY, 2005, 38 (01) : 55 - 63
  • [29] ANTI-RO ANTIBODIES IN HEALTHY MOTHERS AND THEIR NEWBORNS
    GUZMAN, L
    MARTINEZ, P
    GAYTAN, G
    ARGUELLES, E
    HERRERAESPARZA, R
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 1987, 5 (01) : 93 - 94
  • [30] Anti-Ro Antibodies and Reversible Atrioventricular Block
    Santos-Pardo, Irene
    Martinez-Morillo, Melania
    Villuendas, Roger
    Bayes-Genis, Antoni
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (24): : 2335 - 2337